Characterization of β-lactamase and porin mutants of enterobacteriaceae selected with ceftaroline+avibactam (NXL104)

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 6, 2012, Pages 1354-1358

  Livermore, David M ^a,b   Mushtaq, Shazad ^a   Barker, Kevin ^a   Hope, Russell ^a   Warner, Marina ^a   Woodford, Neil ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

lactamase inhibitors; Ampc lactamases; CTX M 15 lactamases; Outer membrane proteins

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE INHIBITOR; BETA LACTAMASE KPC; CEFTAROLINE PLUS AVIBACTAM; EXTENDED SPECTRUM BETA LACTAMASE; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN F; PORIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL OVERGROWTH; BACTERIAL STRAIN; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENZYME ACTIVITY; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; GENOMIC INSTABILITY; MICROBIAL SENSITIVITY TESTS; MUTANT PROTEINS; PHENOTYPE; PORINS; SELECTION, GENETIC;

EID: 84861121770     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks079     Document Type: Article

References (11)

1. Mushtaq S, Warner M, Williams G et al. Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamases-producing Enterobacteriaceae. J Antimicrob Chemother 2010; 65: 1428-32.
2. Cantón R, Morosini MI, de la Maza OM et al. IRT and CMT β-lactamases and inhibitor resistance. Clin Microbiol Infect 2008; 14 Suppl 1: 53-62.
3. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
4. Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β-lactamases. J Antimicrob Chemother 2006; 57: 154-5.
5. Doumith M, Ellington MJ, Livermore DM et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009; 63: 659-67.
6. Endimiani A, Doi Y, Bethel CR et al. Enhancing resistance to cephalosporins in class C β-lactamases: impact of Gly214Glu in CMY-2. Biochemistry 2010; 49: 1014-23.
7. Hidri N, Barnaud G, Decre D et al. Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC β-lactamases of a Serratia marcescens clinical isolate. J Antimicrob Chemother 2005; 55: 496-9.
8. Adediran SA, Zhang Z, Nukaga M et al. The D-methyl group in β-lactamases evolution: evidence from the Y221G and GC1 mutants of the class C β-lactamases of Enterobacter cloacae P99. Biochemistry 2005; 44: 7543-52.
9. Banerjee S, Pieper U, Kapadia G et al. Role of the omega-loop in the activity, substrate specificity, and structure of class A β-lactamases. Biochemistry 1998; 37: 3286-96.
10. Lee SJ, Kim JY, Jung HI et al. Crystallization and preliminary X-ray crystallographic analyses of CMY-1 and CMY-10, plasmidic class C β-lactamases with extended substrate spectrum. Acta Crystallogr D Biol Crystallogr 2004; 60: 382-4.
11. Delmas J, Chen Y, Prati F et al. Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum β-lactamases. J Mol Biol 2008; 375: 192-201.